Vaccines at Sanofi
In a press release, Sanofi stated that it is purchasing all of the Inhibrx assets associated with the investigational medication INBRX-101. This medication is intended to treat an uncommon genetic condition called alpha-1-antitrypsin insufficiency, which causes lung tissue to gradually deteriorate.
"The inclusion of the promising INBRX-101 asset in our rare disease portfolio supports the company's strategy to diversify our offerings," Sanofi stated in a press release.
After being split off into a separate business, Inhibrx's remaining assets will go public.
The parties intend to conclude the deal in the second quarter of this year.
source: cnn.com
"The inclusion of the promising INBRX-101 asset in our rare disease portfolio supports the company's strategy to diversify our offerings," Sanofi stated in a press release.
After being split off into a separate business, Inhibrx's remaining assets will go public.
The parties intend to conclude the deal in the second quarter of this year.
source: cnn.com
